Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13949
Abstract: Selenoprotein P (SeP; encoded by SEPP1 in humans) is a hepatokine that causes impaired insulin secretion and insulin resistance. Metformin downregulates SELENOP promoter activity through an adenosine monophosphate‐activated kinase–forkhead box protein O3a pathway in hepatocytes. This study… read more here.
Keywords: circulating selenoprotein; predict glucose; selenoprotein; glucose lowering ... See more keywords